GlucoMe and Merck KGaA, Darmstadt, Germany to Collaborate on Digital Diabetes Management Project in Vietnam
YARKONA, Israel, August 22, 2018 /PRNewswire/ --
Digital diabetes platform provider GlucoMe has entered into a pilot collaboration agreement with Merck KGaA, Darmstadt, Germany to evaluate GlucoMe's digital diabetes platform across several hospitals in Vietnam. The project is scheduled to begin in August 2018 and will assess the advantages of GlucoMe's digital diabetes care against the current standard of care in Vietnam.
Vietnam is considered the country with the fastest growing rate of diabetes in Southeast Asia. (Vietnam Association of Diabetes and Endocrinology - VADE [https://saigoneer.com/saigon-health/10900-vietnam-has-highest,-fastest-growing-rate-of-diabetes-in-southeast-asia-expert ] ). Of its 92.7 million population (World Bank [https://data.worldbank.org/country/vietnam ]), around 5 million or 5.4% have diabetes. One of the reasons for these large numbers is the lack of resources and capacity to diagnose, monitor and treat diabetes at local community health centers. As such, patients must travel long distances to reach district, provincial or national level hospitals (WHO [http://www.wpro.who.int/vietnam/mediacentre/features/feature_world_health_day_2016_vietnam/en ] ) for treatment and follow-up appointments.
"The collaboration announced today will evaluate the advantages and acceptance of GlucoMe's digital diabetes care system in a country with a vast diabetes patient population, which today faces a significant lack of resources to effectively manage their condition. We have been impressed by the connectivity and simplicity of GlucoMe's solution, allowing physicians to make data-driven decisions while providing patients with stripped down, easy-to-use devices that are automatically connected to their smartphones. GlucoMe's platform has the potential to trigger an overall paradigm shift in the treatment of diabetes in Vietnam and across emerging markets, through the help of cutting-edge technology. Innovation in the treatment of diabetes is a key pillar of our global strategy and this is a clear example of how technology can significantly improve the quality of care," said Daniel Ruggiero, global Head of Diabetes Strategy at Merck's biopharma business.
GlucoMe's solution will initially be installed at five hospitals. Patients will use GlucoMe's wireless blood glucose monitor to measure their blood sugar levels at home. The clinical data will be synced through GlucoMe's mobile app and analyzed by GlucoMe's Digital Diabetes Clinic and its Control Tower alert system. This will enable medical professionals and their staff to continuously monitor their patients and intervene more efficiently and effectively than it is possible with the current, face-to-face, standard of care. It will also help medical teams prioritize and identify severe and urgent cases for timeliest intervention.
GlucoMe CEO Yiftah Ben-Aharon said, "We are delighted to partner with Merck KGaA, a leading science and technology company, to advance the care of diabetes worldwide. We announced the introduction of GlucoMe's solution in India [https://www.glucome.com/about-us/news/glucome-apollo-sugar-india ] and in Central America [https://www.glucome.com/about-us/news/glucome-diaman-announce-launch-central-america ] in the first two quarters of 2018. Today, we are proud to announce the initiative in Vietnam. Digital diabetes care has particular value for countries with high prevalence but with limited resources for monitoring and treating the condition. We are happy to be the first on the scene where a digital diabetes care solution is crucially needed. We intend to work our way around the world with the goal of modernizing diabetes care for the benefit of patients, medical teams and payers."
About Merck KGaA, Darmstadt, Germany in Diabetes
Merck KGaA Darmstadt, Germany is a global leading player in the type 2 Diabetes area and originator of the orally administered antihyperglycemic drug Glucophage(R) (metformin) which has more than sixty years of clinical use and is the first line recommended monotherapy in the type 2 diabetes treatment guidelines. In May 2017, Merck KGaA Darmstadt, Germany received label extension for the administration of Glucophage(R) for non-diabetic hyperglycemia (commonly known as prediabetes) in the United Kingdom and is currently seeking this indication in additional countries worldwide.
About GlucoMe
GlucoMe [http://www.glucome.com ] is a digital health company developing and marketing a comprehensive digital diabetes care solution that streamlines and simplifies diabetes care for patients, caregivers, and medical professionals. The GlucoMe platform includes: affordable wireless blood glucose and insulin pen monitors that uniquely operate with audio connectivity; a mobile app compatible with iOS and Android devices; a Digital Diabetes Clinic, which includes a cloud-based diabetes management software for healthcare professionals; a Control Tower, which prioritizes urgency based on real-time patient data; and a Decision Support System, which analyzes the history of data and provides the medical team with treatment recommendations.
For additional information about GlucoMe visit www.glucome.com [http://www.glucome.com ] and follow the company on LinkedIn [https://www.linkedin.com/company/glucome/?trk=biz-companies-cym ] and Facebook [https://www.facebook.com/glucome ].
Press Contact:
Angelica Khachaturova
angelica@glucome.com
+972-50-908-0181
SOURCE GlucoMe
